Efficacy and Safety of 80mg Osimertinib in Patients With Non-small Cell Lung Cancer(NSCLC)

Condition:   Non-small Cell Lung Cancer (NSCLC) Intervention:   Drug: 80mg Osimertinib Sponsors:   Samsung Medical Center;   AstraZeneca Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials